

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/127		A1	(11) International Publication Number: WO 96/40062 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/08619 (22) International Filing Date: 6 June 1996 (06.06.96)		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/483,090 7 June 1995 (07.06.95) US		Published <i>With International search report.</i>	
(71) Applicant: GEORGETOWN UNIVERSITY [US/US]; Ryan Administration Building, 37th and O Streets, N.W., Washington, DC 20057 (US).			
(72) Inventors: THIERRY, Alain; Apartment #501, 4970 Battery Lane, Bethesda, MD 20814 (US). DRITSCHILO, Anatoly; 8101 Fenway Road, Bethesda, MD 20817 (US).			
(74) Agents: BENT, Stephen, A. et al.; Foley & Lardner, Suite 500, 3000 K Street N.W., Washington, DC 20007-5109 (US).			
(54) Title: A METHOD OF TRANSFECTION OF CELLS USING LIPOSOMALLY ENCAPSULATED NUCLEIC ACIDS			
(57) Abstract			
<p>An improved method for encapsulating high molecular weight nucleic acids in liposomes, which provides for high nucleic acid entrapment efficiencies, is provided. The resulting compositions provide enhanced <i>in vitro</i> and <i>in vivo</i> transfection and are useful, for example, in producing cell lines expressing a desired nucleic acid sequence.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NB	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mall	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

A METHOD OF TRANSFECTION OF CELLS
USING LIPOSOMALLY ENCAPSULATED NUCLEIC ACIDS

BACKGROUND OF THE INVENTION

Cells that express heterologous gene products are valuable as research tools, as "factories" for the production of gene products, and for gene therapy. It has therefore become increasingly important to be able to custom engineer cells with heterologous polynucleotide constructs rapidly and inexpensively. A major factor in the time and cost of generating such cells lines is the efficiency with which polynucleotides can be introduced and stably incorporated into the desired cells.

Currently, a variety of methods exist for transfecting polynucleotides into target cells. Such methods include conventional means such as calcium phosphate and polycation-mediated transfection, as well as protoplast fusion, viral and retroviral infection, microinjection and electroporation.

Another method recently investigated for delivery of polynucleotides into cells involves the administration of liposomally-encapsulated nucleic acids. Such methods originated in the early 1980's when Papahadjopoulos et al. disclosed the encapsulation of biologically-active materials, such as nucleic acids and proteins, in liposomes. These liposomes were then used for delivery of the biologically active materials to target cells. See, e.g., U.S. Patent No. 4,241,046; U.S. Patent No. 4,235,871; U.S. Patent No. 4,394,448. See also, Lasic et al., *Science* 267:1275 (1995).

Such methods have been improved in order to enhance efficiency of the transfection process. For example, conjugating liposomes to ligands which selectively bind to targeted cells is known to enhance the efficiency of delivery to desired cells. Relevant patents which disclose the conjugation of liposomes to cell-targeting moieties, in particular, to antibodies, are e.g., U.S. Patent No. 5,210,040; U.S. Patent No. 4,957,735; U.S.

Patent No. 4,925,661; U.S. Patent No. 4,806,466; U.S. Patent No. 4,762,915; U.S. Patent No. 4,708,933; U.S. Patent No. 4,483,921; U.S. Patent No. 4,480,041; U.S. Patent No. 4,429,008.

5 pH-sensitive liposomes also provide for enhanced delivery of targeted nucleic acids into cells. For example, U.S. Patent No. 4,789,633 and Huang et al., *Proc. Nat'l. Acad. Sci. USA* 87:7851 (1987) disclose pH-sensitive DNA containing liposomes which fuse with cell
10 membranes at a pH below 7, thereby facilitating introduction of the desired DNA. While such liposomes enable improved delivery of foreign DNA's, they are still quite inefficient, generally because of poor entrapment efficiency. This poor entrapment efficiency means both
15 that large quantities of DNA are wasted in preparing the liposomes, and that large quantities of liposomes must be used to achieve delivery of a given amount of DNA to cells.

20 Another method for achieving delivery of DNA containing liposomes involves the administration of complexes of DNA with cationic lipids. For example, U.S. Patent No. 5,227,170 teaches encapsulation of oligonucleotides in cationic lipid complexes which further comprise a divalent cation solution containing
25 the desired oligonucleotides and which have an osmolarity less than that of the internal aqueous phase. See also, Felgner et al., *Proc. Nat'l. Acad. Sci. USA*, 84:7413 (1987). Due to their cationic character, these liposomes can bind to serum proteins, thereby leading to
30 inactivation of the oligonucleotides contained therein. Also, osmotic-dependent liposomes are known in the literature, i.e., as disclosed by U.S. Patent No. 5,049,392.

35 Methods for optimizing the size of liposomes also are known. For example, U.S. Patent No. 4,532,089 teaches a method for preparing giant liposomes. Also, U.S. Patent No. 4,529,561 teaches a method for preparing liposomes in desired size ranges. Further, U.S. Patent No. 5,223,263

teaches liponucleotide containing liposomes and the use thereof in delivery of the liponucleotides to desired cells.

Thus, it is clear that many methods for delivery of nucleic acids into cells are known in the art, as are methods which rely on liposomally-mediated introduction of nucleic acids. Conventional liposome encapsulation methods are subject to many constraints. For example, conventional methods for encapsulation of nucleic acids into liposomes are limited by poor entrapment efficiencies. That is, only a small percentage of the initial nucleic acid used actually becomes encapsulated. As discussed *supra* this is undesirable because it is inefficient both with respect to its use of DNA and with respect to the quantity of liposomes that must be used to deliver a given amount of DNA.

Also, most conventional methods for liposome encapsulation of nucleic acids are suitable only for encapsulation of small nucleotides, e.g., oligonucleotides. This is disadvantageous since expression of heterologous gene products in cells often requires the introduction of much larger DNA sequences that include not only coding regions, but also other *cis*-acting controls for regulating gene expression, such as promoter and enhancer sequences, operator sequences and the like, as well as a ribosome binding site, an initiation codon and transcription termination and polyadenylation signals. Buffer regions, origins of replication for extra-chromosomal replication, and flanking regions with homology to a target site for targeted chromosomal insertion by homologous recombination may also be included.

Present methods do not permit the efficient encapsulation of large DNA vectors such as plasmids and phagemids. This is particularly disadvantageous for those vectors that are designed to be maintained in an episomal state, i.e., extrachromosomally. These vectors can avoid the potential problems which occur during non-

targeted integration of a heterologous DNA into a host cell genome, e.g., oncogene activation, loss of recombined sequences, inactivation of essential genes, inefficient level of expression of the heterologous DNA or inadequate means for controlling level of gene expression. Large DNA vectors are also usually required when targeted integration into a chromosome by the method of homologous recombination is desired. This is because relatively large regions of flanking DNA are used to ensure that insertion occurs at a preferred chromosomal site, thereby avoiding the problems discussed *supra* associated with random insertion.

It is apparent, therefore, that a more efficient method of administering large DNA molecules into cells is greatly to be desired. In particular, it is desirable that an improved method of encapsulating high molecular weight nucleic acids into liposomes with high entrapment efficiencies is greatly to be desired.

SUMMARY OF THE INVENTION

Therefore, it is an object of the invention to provide a method for encapsulating high molecular weight nucleic acids and which also provides for high entrapment efficiency, in comparison to known methods for producing liposomally-encapsulated nucleic acids.

It is another object of the invention to provide a method for transfecting cells which is fast, inexpensive and reliable, in comparison to available methods for transfecting cells.

It yet is another object of the invention to provide a liposome comprising high molecular weight nucleic acids, e.g., comprising DNA's ranging from about 1.0 kB to about 20 kB, and preferably from about 5 to 18 kB.

In accomplishing the foregoing objects of the invention, there has been provided, in accordance with one aspect of the current invention, a method for encapsulating in liposomes nucleic acids ranging from about 1 to 20 kB and, preferably, from about 5 to about 18 kB, comprising the steps of (i) incubating a hydrated

lipid film for an effective time at reduced temperature, where the hydrated lipid film is formed by addition of a concentrated aqueous solution of a high molecular weight nucleic acid to a dried lipid film; (ii) adding a minimum 5 effective amount of phosphate buffered saline solution to the hydrated lipid film and vortexing for a time sufficient to generate liposomes and to swell the liposomes; and (iii) vortexing the resulting swelled liposomes. The method may also further comprise the step 10 of (iv) removing unencapsulated nucleic acid from said liposomes by washing said liposomes. The washing may be achieved by centrifugation.

In accordance with another aspect of the invention, the lipid film comprises at least one lipid selected from 15 the group consisting of dimyristoyl-diglycerol, phosphatidylethanolamine, phosphatidylcholine, phosphatidic acid, lysophosphatidylcholine, phosphatidylserine, sphingolipids, phosphatidylglycerol, sphingomyelin, cardiolipin, glycolipids, gangliosides, 20 cerebrosides, cholesterol, tocopherol, and retinol.

In accordance with a further aspect of the invention the lipid film comprises dimyristoyldiglycerol, phosphatidylethanolamine and cholesterol, in a relative molar ratio of about 5:5:7 respectively.

25 In accordance with yet another aspect of the invention the nucleic acid solution has a concentration of 1-5 mg/ml, and the nucleic acid solution is added to the dried lipid film in a ratio of less than or equal to about 1.6 μ l per mg of lipid. The effective time for the 30 incubating step is preferably at least 12 hours, and the time for forming and swelling the liposomes is at least 30 minutes.

In accordance with still another aspect of the 35 invention the size of the nucleic acid is preferably from about 1 kB to about 25 kB, or more preferably from about 5 kB to about 18 kB.

In accordance with a still further aspect of the invention there has been provided a method for

transfected cells comprising contacting a cell with an effective amount of swelled nucleic acid-containing liposomes, wherein the liposomes are prepared as described above. The nucleic acid is preferably a 5 plasmid, a phagemid, or a cosmid.

In accordance with still another aspect of the invention there has been provided a liposome comprising a high molecular weight nucleic acid, produced by the method described above. In a preferred embodiment the 10 nucleic acid has a size of at least 2 kB, and at least 25% of the liposomes contain the nucleic acid. In another preferred embodiment the nucleic acid has a size of at least 5 kB, and at least 10% of the liposomes contain the nucleic acid.

15 In accordance with yet aspect of the invention there has been provided a transfected cell prepared by the method described above. In a preferred embodiment the liposome contains a high molecular weight DNA encoding an antisense RNA, a ribozyme, or a therapeutic protein.

20 In accordance with a further aspect of the invention there has been provided a method for preparing a liposome-encapsulated nucleic acid comprising the steps of (i) incubating a hydrated lipid film for about 2 hours at about 4°C, wherein the hydrated lipid film is 25 formed by addition of a concentrated aqueous solution of a high molecular weight nucleic acid to a dried lipid film in a ratio of less than or equal to about 1.6 μ l of DNA solution per mg of lipid; (ii) adding a phosphate buffered saline solution to the hydrated lipid film in a ratio of less than or equal to about 1.6 μ l per 30 mg of lipid, and vortexing for a time sufficient to generate liposomes and to swell the liposomes; and (iii) vortexing the resulting swelled liposomes, whereby at least 25% of said liposomes contain the nucleic acid. In 35 a preferred embodiment the high molecular weight DNA encodes a tissue-specific promoter.

In accordance with another aspect of the invention there is provided a liposome prepared by the methods

described above, wherein the therapeutic protein is selected from the group consisting of platelet-derived growth factor, epidermal growth factor, interleukins 1-14, granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor, tumor necrosis factor, leukemia inhibitory factor, amphiregulin, angiogenin, betacellulin, calcitonin, ciliary neurotrophic factor, brain-derived neurotrophic factor, neurotrophins 3 and 4, nerve growth factor, colony stimulating factor-1, endothelial cell growth factor, erythropoietin, acidic and basic, fibroblast growth factor, hepatocyte growth factor, heparin binding EGF-like growth factor, insulin, insulin-like growth factors I and II, interferons α , β , and γ , keratinocyte growth factor, macrophage inflammatory protein α and β , midkine, oncostatin M, RANTES, stem cell factor, transforming growth factors α and β , and vascular endothelial growth factor.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides an improved method for the encapsulation of high molecular weight nucleic acids in liposomes, wherein a higher nucleic acid entrapment efficiency is achieved than can be achieved by conventional methods for encapsulating nucleic acids in liposomes. In the present invention, entrapment efficiency is defined as the percentage of the initial amount of the nucleic acid used which becomes encapsulated in the resulting liposomes.

This improved method also provides liposomal compositions in which a greater proportion of the liposomes actually contain the desired nucleic acids, than can be achieved with conventional methods for encapsulating nucleic acids in liposomes. Additionally, each liposome comprises a higher nucleic acid content, on average, than liposomes generated by conventional techniques.

These characteristics are advantageous for several reasons. First, the high encapsulation efficiency, which

is generally at least 25%, and usually 50% based upon the initial amount of nucleic acid, but which may be as high or even higher than 90%, reduces cost since it requires less nucleic acid than conventional liposome encapsulation processes. Second, high entrapment efficiency improves the performance quality of the nucleic acid-containing liposomes because (i) a greater portion of the liposomes contain nucleic acid and (ii) the average nucleic acid content is higher than in liposomes generated by conventional methods. This translates into improved delivery of nucleic acids to target cells and, accordingly, there is a greater probability that a nucleic acid will be delivered to any given target cell. Because each nucleic acid delivered may not achieve stable transfection, a higher delivery rate improves the chance that a cell will be produced which expresses the desired product.

The present invention provides for the efficient encapsulation of high molecular weight polynucleotide molecules. The terms "nucleic acid" or "polynucleotide" as used herein are considered interchangeable unless otherwise indicated, and encompass DNA, RNA or a mixture of DNA and RNA. Nucleic acids according to the present invention may also include any strand structure, e.g., single-, double- or triple-stranded polynucleotide structures or mixtures thereof. Also, the nucleic acids may comprise a linear or circular structures, e.g., plasmids, phagemids, cosmids, etc.

As used herein, "high molecular weight" polynucleotide refers to a polynucleotide molecule that comprises at least one coding sequence that can be transcribed when the polynucleotide is introduced into a host cell. This transcription can produce an mRNA molecule that can then be translated to produce a polypeptide or protein, or it can produce an antisense RNA molecule. Transcription of the coding sequence of the HMW polynucleotide is preferably under the control of *cis*-acting regulatory elements, such as enhancer

sequences, operator sequences and the like, and the polynucleotide also contains a ribosome binding site, an initiation codon and transcription termination and polyadenylation signals. The definition of HMW polynucleotides as used herein is, therefore, generally understood to mean polynucleotides that contain such regulatory elements. The HMW polynucleotide may also contain other elements such as origins of replication as are commonly found on polynucleotides used for transfection.

The present invention provides for the efficient encapsulation of large vectors, including those which contain sequences that permit stable, episomal maintenance and those which encode multigene cassettes. This is significant, in the case of episomal constructs, because integration of the desired nucleic acid into the host cell's genome may have a negative impact on the transfection process. For multigene cassettes, it also is important as coordinate regulation of the encoded genes can be more easily achieved.

The nucleic acids which may be encapsulated according to the present method may range in size from as small as about 500 bases to about 50 kilobases. In a preferred embodiment, the encapsulated nucleic acids will comprise DNA's ranging from about 1.0 to 25 kB and, preferably, from about 5 to about 18 kB.

The nucleic acids which may be encapsulated according to the present method may comprise sense or antisense polynucleotides. For example, antisense oligonucleotides may be encapsulated which selectively inhibit the expression of target DNA's. For example, antisense oligonucleotides may be encapsulated which are complementary to viral sequences and utilized for antiviral treatments, e.g., hepatitis, AIDS viral infection, papillomavirus infection, etc. The use of antisense oligonucleotides for genetic therapy has been reported in the literature. See Stein and Chang, *Science* 261: 1004 (1993). Also, ribozymal RNA's may be

encapsulated and used to study gene expression or for genetic therapy.

In a preferred embodiment, the encapsulated nucleic acids will comprise an episomal element, e.g., a plasmid which contains one or more genes which are to be expressed in target cells. An episomal element containing an origin of replication that is recognized by the replication functions of the host cell will be stably maintained in the cell as an extrachromosomal element, thereby allowing stable expression of genes encoded on the element. In general, these genes will cause the target cell to produce a heterologous expression product, or acquire an altered phenotype. If the episomal element does not contain an origin or replication that is recognized by the host cell, the expression product will be produced only transiently.

Another utility for the subject liposomal encapsulated nucleic acids will comprise producing cells or animals which express a defective gene or genes. Thereby, the resulting cells or animals may be used as *in vitro* or *in vivo* models for assessing the efficacy of potential therapeutic agents.

A further utility for the liposomally encapsulated nucleic acids of the invention is for gene therapy, that is for introducing into cells DNA constructs that encode a therapeutic product. The therapeutic product can be, for example, an antisense RNA or ribozyme RNA molecule, or it can be a therapeutic protein. A "therapeutic protein" as used herein refers to a peptide, polypeptide, or protein that, when confers a therapeutic benefit to a host when administered to the host, or when it is expressed in cells of the host. The gene therapy can be *in vivo*, in which the liposomally encapsulated DNA constructs are introduced directly into a host animal, preferably a human, or can be *ex vivo*, in which isolated cells are first transfected with the liposomally encapsulated DNA constructs, and are then reintroduced into a host animal. *Ex vivo* gene therapy in humans is

described in U.S. patent 5,399,346, which is hereby incorporated by reference in its entirety. See also Tolstoshev, Annu. Rev. Pharmacol. Toxicol. 33:573-96 (1993), for a general review of gene therapy, which is 5 also incorporated herein by reference in its entirety.

The subject nucleic acid containing liposomes will, in general, be made by a method comprising:

- (i) forming a lipid film under reduced pressure,
- 10 (ii) hydrating the lipid film by the addition of an effective amount of a nucleic acid containing solution;
- (iii) incubating the mixture for an effective time period at reduced temperature;
- 15 (iv) adding a phosphate buffered solution to the hydrated lipid film and vortexing;
- (v) incubating at ambient temperature for a time sufficient to facilitate swelling; and
- (vi) vortexing the resultant swelled composition to produce nucleic acid containing liposomes.

Typically, there will be an intervening step between 20 step (iv) and step (v) wherein additional phosphate buffered saline solution is added and the mixture is again vortexed. Also, after step (vi), the unencapsulated (free) nucleic acids typically will be removed. This may be effected, for example, by washing 25 the liposomes repeatedly while centrifuging in a phosphate buffered saline solution.

In general, about 20 μ mole (about 0.64 mg) of lipid is dried under reduced pressure (30mm Hg) in a 40 mm² surface of a round-bottom glass flask or tube. The 30 resulting dry lipid film is hydrated with about 1.4 μ l of aqueous solution containing DNA to be encapsulated. Generally, a container having a mean surface area of about 10 to 200 mm² is used, under a reduced pressure of about 1 to 50mm Hg, and a hydration volume of about 0.7 to 2 μ l.

Step (i) typically will be effected by forming a lipid film using any lipid or mixture of suitable lipids which are evaporated under a vacuum. The lipid mixture

used to make this lipid film will comprise any lipid or mixture of lipids which provides for suitable nucleic acid entrapment efficiency.

Examples of lipids suitable for use in the invention include, e.g., known vesicle or liposome forming compounds such as phosphatidylcholine, both naturally occurring and synthetically prepared, phosphatidic acid, lysophosphatidylcholine, phosphatidylserine, phosphatidyl ethanolamine, sphingolipids, phosphatidylglycerol, sphingomyelin, cardiolipin, glycolipids, gangliosides, and cerebrosides such as soybean phospholipids. Other suitable lipids include steroids, cholesterol, aliphatic amines such as long chain aliphatic amines and carboxylic acids, long chain sulfates and phosphates, diacetyl phosphates, butylated hydroxy toluene, tocopherol, retinol and isoprenoid compounds which may confer desired properties to the formed liposomes.

Also, synthetic phospholipids containing either altered aliphatic portions such as hydroxyl groups, branched carbon chains, cyclo derivatives, aromatic derivatives, ethers, amides, polyunsaturated derivatives, halogenated derivatives or altered hydrophilic portions containing carbohydrate, glycol, phosphate, phosphamide, quaternary amines, sulfate, sulfonyl, carboxy, amine, sulphydryl, imidazole groups and combinations of such groups can be either substituted or intermixed with the above-mentioned lipids which may be used in the present invention. Lipids suitable for use in preparing liposomes are well known in the literature, and are described, e.g., in U.S. Patent No. 4,201,767; U.S. Patent No. 4,235,877; U.S. Patent No. 4,241,046; U.S. Patent No. 4,261,975; and U.S. Patent No. 4,394,448, all of which are incorporated by reference in their entireties.

The present invention embraces the use of any lipid or combination which provides the desired encapsulation efficiency which, in general, will be at least about 25%, relative to the initial amount of nucleic acid used for

encapsulation. In a preferred embodiment the encapsulation efficiency will be preferably at least 50%, more preferably 70%, and still more preferably will be in the range from about 70% to about 90%

5 Preferred lipids include dimyristoyl phosphatidyl glycerol, cardiolipin, phosphatidyl choline, phosphatidyl glycerol, sphingomyelin, and cholesterol. In a particularly preferred embodiment, the lipids used to make the lipid film comprise a mixture of 10 dimyristoylglycerol, phosphatidylethanolamine and cholesterol. Most preferably, the molar ratio of these lipids is about 5:5:7 of dimyristoylglycerol, phosphatidylethanolamine and cholesterol, respectively.

15 Step (ii), the hydration step, in general, comprises the addition of an effective amount of a nucleic acid-containing aqueous solution to a dried lipid film. Preferably, this solution will comprise a highly concentrated, aqueous, nucleic acid solution and, more preferably, a concentrated DNA containing solution. A 20 preferred concentration range for the DNA solution is from about 1 mg/ml to about 5 mg/ml, but concentrations outside this range may also be used, for example from about 0.01 mg/ml to about 20 mg/ml, or up until the DNA solution is saturated. In the examples, the solution 25 comprises plasmids in an aqueous solution at a concentration of about 1-2 mg/ml. This concentrated nucleic acid solution is added to the dry lipid film in an amount sufficient to provide hydration and to achieve the desired amount of nucleic acid encapsulation.

30 For example, in one instance, a 2 mg/ml DNA plasmid solution was utilized, at 1.6 μ l solution/mg lipid, to facilitate hydration. This amount may be varied as needed. A suitable amount of the nucleic acid-containing solution will vary from about 1.7 to 17 μ g of DNA per mg 35 of lipid if utilizing a nucleic acid solution having a concentration of about 1-5 mg/ml of DNA.

As discussed *supra*, the nucleic acid contained in this solution may comprise DNA, RNA or a mixture thereof,

and may comprise linear or circular structures. Also, the encapsulated nucleic acids may be single or multi-stranded and may comprise sense or antisense nucleic acid sequences. In the preferred embodiment, the nucleic acids will comprise DNA constructs having a size ranging from about 5 to about 18 kilobases. In general, such DNA constructs will contain a gene or genes which are to be expressed in the targeted cells. The DNA construct also preferably will contain suitable regulatory sequences which provide for the expression of these genes, in addition to sequences that provide for these DNA constructs to autonomously replicate in target cells if necessary, and also suitable selectable markers, e.g., antibiotic resistance markers. In general, these genes will be expressed under the control of regulatable promoters.

In the most preferred embodiments, the DNA constructs will contain a gene or genes which produce a therapeutic or valuable gene product. Examples of such gene products include, but are not limited to, therapeutic lymphokines, cytokines, hormones, cell adhesion molecules, enzymes or enzyme inhibitors, receptors, ion channels, transcription factors, protein kinases, protein phosphatases, and cellular antigens for generating an immune response in a host. Alternatively the DNA constructs will contain suicide genes, tumor suppressor genes, genes encoding antisense RNAs, or genes that induce or prevent cellular apoptosis.

Examples of lymphokines and cytokines that can be encoded by the liposomally-encapsulated DNA constructs of the invention include platelet-derived growth factor, epidermal growth factor, interleukins 1-14, granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor, tumor necrosis factor, leukemia inhibitory factor, amphiregulin, angiogenin, betacellulin, calcitonin, ciliary neurotrophic factor, brain-derived neurotrophic factor, neurotrophins 3 and 4, nerve growth factor,

colony stimulating factor-1, endothelial cell growth factor, erythropoietin, acidic and basic, fibroblast growth factor, hepatocyte growth factor, heparin binding EGF-like growth factor, insulin, insulin-like growth factors I and II, interferons α , β , and γ , keratinocyte growth factor, macrophage inflammatory protein α and β , midkine, oncostatin M, RANTES, stem cell factor, transforming growth factors α and β , and vascular endothelial growth factor. Examples of cell adhesion molecules include integrins, cadherins, selectins, and adhesion molecules of the immunoglobulin superfamily, such as VCAM, ICAM, PECAM, and NCAM. Examples of tumor suppressor genes include p53, DCC, Rb, and MTS1. Those of skill in the art will recognize that other genes can also be used in the invention.

In addition, as discussed *supra*, the DNA construct will contain regulatory elements that can control replication of the construct within the cell, as well as transcription and translation of genes encoded on the construct. For use in *in vivo* gene therapy it is sometimes useful for these regulatory elements to be tissue specific. The term "tissue-specific promoter" or "tissue-specific transcriptional regulatory sequence" or indicates a transcriptional regulatory sequence, promoter and / or enhancer that is induced selectively or at a higher level in cells of the target tissue than in other cells. For example, tumor cell-specific promoters include promoters that are induced selectively or at a higher level in a particular cell type or a tumor cell. Tissue specific promoters are known in the art. Examples include: the alpha-actin promoter (Shani, *Mol. Cell. Biol.*, 6:2624 (1986)); the elastase promoter (Swift et al., *Cell*, 38:639 (1984)); the alpha-fetoprotein promoter (Krumlauf et al., *Nature*, 319:224-226 (1985)); the beta-globin promoter, (Townes et al., *EMBO J.*, 4:1715 (1985)); the human growth hormone promoter (Behringer et al., *Genes Dev.*, 2:453 (1988)); the insulin promoter (Selden et al., *Nature*, 321:545 (1986)) and a prostate-specific

promoter (Allison et al., Mol. Cell. Biol., 9:2254 (1989)).

Step (iii) of the subject method comprises incubating the hydrated lipid film for about 12 to 24 hours at a 5 reduced temperature, for example at about 4°C.

Step (iv) will in general comprise the addition of a minimum effective amount of a phosphate buffered saline solution followed by vortexing. This minimum effective amount of the added phosphate buffer solution will be 10 less than about 1.6 μ l/mg of lipid, and preferably will range from about 0.5 to 1.5 μ l/mg lipid. In the exemplified embodiment, 1.4 μ l of phosphate buffered saline solution was added per mg of the hydrated lipid.

In most cases, the initial vortexing will be followed 15 by another step wherein additional phosphate buffered saline solution is added followed by vigorous vortexing. This may be effected by the addition of a second phosphate buffered saline solution in an amount less than about 1.6 μ l/mg of lipid, and preferably from about 0.5 to about 1.5 μ l/mg lipid.

Step (v) comprises incubating the mixture obtained from step (iv) for a time sufficient to permit swelling and, thereafter, generation of liposomes. In general, this will comprise incubating the mixture at ambient 25 temperature for at least about 30 minutes, and preferably at least about 2 hours. In the exemplified embodiment, the swelling time was 2 hours. Those of skill in the art will recognize, however, that this time may be varied with only routine experimentation to optimize the formation of liposomes. Additional PBS solution (8 μ l/mg of lipid) may optionally be added at this point to dilute 30 the liposome solution.

Step (vi) comprises homogenization and resuspension of the swelled liposome composition, usually by 35 vortexing. With liposomes containing smaller oligonucleotides this step is conveniently and efficiently carried out by sonication of the liposome mixture. This procedure is not suitable, however, for

liposomes containing larger DNA constructs, which degrade rapidly under sonication conditions. It has been found, unexpectedly, that thorough mixing, homogenization and resuspension can be achieved by vortexing the liposome mixture.

As discussed *supra*, after the nucleic acid-containing liposomes are produced, the composition preferably will be treated to remove the free nucleic acids. This may be effected by any suitable method which does not adversely affect the liposomes, for example, by washing the liposomes in a suitable solution, e.g., phosphate buffered saline, followed by centrifugation.

Nucleic acid-containing liposomes produced in this manner may be used immediately or may be stored under favorable conditions, e.g., at about 4°C. Liposomes according to the present invention are stable for up to three weeks.

After the liposomes are produced, the encapsulation efficiency may be ascertained by known methods. For example, a DNA sample containing radiolabeled plasmid DNA constructs can be employed. This permits determination of the relative amounts of liposome-contained and free radioactivity.

The subject method reliably provides for nucleic acid entrapment efficiencies ranging from at least 25 to 50%, and more typically about 70 to 90% based upon the initial amount of nucleic acid contained in the sample, e.g., a DNA plasmid containing sample.

These liposomes may be used for both *in vitro* or *in vivo* transfection of nucleic acids into targeted cells. The targeted cells can be any cell whose cellular membrane is comprised of a lipid bilayer, and in general will comprise eukaryotic cells, and preferably mammalian cells, more preferably murine or human cells.

If the subject liposomes are to be administered *in vivo*, it may be preferable to conjugate these liposomes to a moiety which provides for the liposome to bind to targeted cells. Examples of such targeting moieties will

include antibodies, or ligands which selectively bind to the targeted cells. Methods for conjugating liposomes to targeting moieties, e.g., antibodies are well known in the art and are discussed, *supra*. For example, the 5 subject liposomes may be conjugated to an antiviral antibody if the liposomes contain an antiviral construct, e.g., a nucleic acid which encodes a gene product which renders transfected cells susceptible to a particular drug.

10 If transfection is effected *in vitro*, a suitable amount of the subject liposomes will be added to a cell culture medium containing the targeted cells. A suitable amount of the liposome composition may range from about 0.12 to 1.2 mg of liposome per 10^6 cells, or from about 15 0.1 to about 10 μ g of encapsulated DNA per 10^6 cells. Those of skill in the art will realize, however, that this amount can vary, depending upon factors such as the lability of the particular targeted cell, its resistance to transfection, whether the liposomes contain smaller or 20 larger nucleic acids, the activity of the particular gene, and the desired level of gene expression.

The resulting liposomally-transfected cells may be used for various applications. For example, the cells 25 may be used to express a polypeptide encoded by the incorporated nucleic acids, e.g., a desired mammalian gene product. Also, if the incorporated nucleic acids result in the cells expressing a particular genetic defect, the cells may be used as models for studying the 30 efficacy of proposed therapies for the particular genetic defect.

Alternatively, if *in vitro* liposomal transfection results in the incorporation of genes which compensate for some genetic defect, or which encode a moiety such as an antisense RNA, ribozyme, or therapeutic protein, these 35 cells may be administered to a host in need of genetic therapy. See U.S. patent 5,399,346.

If the nucleic acid-containing liposomes are to be used *in vivo*, they are administered to a host in need of

genetic therapy. Another variation on *in vivo* use is for the generation of genetic defects, e.g., transgenic or "knock-out" mice which are useful in the study of disease. An example of genetic therapy in a patient is 5 when a DNA construct encoding human leukocyte antigen B7 (HLAB7) is encapsulated in a liposome as described *supra* and injected directly into the tumor lesions of a patient suffering from cutaneous melanoma, as described in Nabel et al., Proc. Natl. Acad. Sci. 90:11307 (1993), which is hereby incorporated by reference in its entirety. The 10 HLAB7 stimulates the host immune response against the melanoma cells.

Generally, an *in vivo* liposomal dosage will range from about 0.2 to 20 mg/kg of body weight, and preferably 15 from about 2 mg to 10 mg/kg of body weight. The amount will, of course, depend on the particular genetic defect, the type of nucleic acid encapsulated, the desired level of gene expression, the amount of nucleic acid contained in the liposomes, and other factors as discussed *supra*.

20 A particular advantage of the present invention is that it provides for the delivery of episomal elements to targeted cells, e.g., DNA plasmids. Preferably, the liposomes will be conjugated to a targeting moiety, e.g., an antibody to enhance delivery, when the desired target 25 is an *in vivo* one, e.g., a tumor. This will avoid some of the problems which occur via integration of heterologous nucleic acids into normal host cell genomes.

Liposome compositions according to the present 30 invention may be administered with additional substances, e.g., pharmaceutical carriers and excipients. Suitable carriers or excipients are described in REMINGTON'S PHARMACEUTICAL SCIENCES: DRUG RECEPTORS AND RECEPTOR THEORY, (18th ed.), Mack Publishing Co., Easton PA (1990). The choice of carrier, diluent, excipient, etc. 35 will depend upon the desired mode of delivery. The liposomal compositions of the invention can be administered by any route currently known for delivering polynucleotide molecules to cells, including, but not

limited to intravenous or intramuscular injection, transdermally as a component of an ointment or cream, intratracheally, intranasally, or orally by aerosol or by drip, rectally, etc. Preferably, however, the liposomes
5 will be administered by injection.

Additionally, liposomes according to the present invention may be administered *in vivo* in combination with other medicaments suitable for use in treating a particular disorder. For example, if the liposomes
10 contain a "suicide gene" which renders targeted cells susceptible to a particular drug, it may be desirable to coadminister liposomes in with the drug. The drug may be, but need not be, liposomally encapsulated.

The efficiency of *in vivo* or *in vitro* transfection
15 may be measured by standard methods. See Sambrook *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL, Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1989). For example, the expression of genes encoded on a liposomally encapsulated DNA construct
20 transfected into cells *in vitro* can be studied by Northern blotting or RNA PCR to measure production of RNA transcripts, and by Western blotting, immunoprecipitation, and *in situ* immunohistochemistry to detect and measure protein production. Integration of
25 the DNA into the host cell chromosome can be determined by PCR or by Southern blotting. The same methods are used to determine whether tissue treated *in vivo* contains transfected genes, or is expressing gene products of the transfected genes. This is preferably carried out on a
30 biopsy sample of the tissue of interest.

The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.

EXAMPLE 35: Preparation of Liposomally Encapsulated DNA

Liposome-encapsulated DNA was prepared by thin lipid hydration using a highly concentrated DNA solution. Specifically, dimyristoylphosphatidylglycerol,

phosphatidylethanolamine, and cholesterol were mixed at a 5:5:7 molar ratio in a round-bottom flask, with a total weight of 6.4 mg. A thin lipid film was formed by rotary evaporation under vacuum. The resultant dry lipid film
5 was then hydrated by adding 10 μ l of a 2 mg/ml solution of 32 P-labeled plasmid DNA. The hydrated lipid film was then incubated overnight at 4°C. After this incubation period, 10 μ l of phosphate buffer saline (PBS) were added to the hydrated lipid film and the mixture was vortexed.
10 After vortexing, supplemental PBS was added, specifically 1.4 μ l/mg lipid of PBS, and the mixture was vigorously vortexed. This vortexed composition was then allowed to swell for 2 hours at room temperature and the resulting liposome containing suspension was vortexed. On some
15 occasions, additional PBS (8 μ l/mg of lipid) was then added if necessary. Free (unencapsulated) DNA was then removed by washing the liposomes by centrifugation (3X at 70,000 g for 30 minutes) in PBS.

The encapsulation efficiency was then determined by
20 counting the radioactivity comprised in an aliquot of a liposomal DNA preparation. The entrapment rate was found to be 70-90% based upon the initial counts. Moreover, this result was reliably reproducible in additional trials.

25 **EXAMPLE 2: In vitro Transfection of Mammalian Cells Using Liposomally Encapsulated DNA Plasmids**

Squamous carcinoma SCC 35 cells were transfected with plasmids pSV40neo and pRSVcat which contain the neomycin resistance gene and the chloramphenicol acetyltransferase gene, respectively. These plasmids were chosen to allow measurement of the efficiencies of transient and stable transfection of cells transfected by various transfection methods.

35 pSV40neo (Promega Corp., Madison, WI) contains a gene for neomycin resistance, thereby allowing transfected cells that express the gene product to survive in culture in medium containing neomycin. When the culture is maintained long-term in neomycin, the only cells that

survive are ones that have stably integrated the neo gene into their chromosomes.

5 pRSVcat (Promega Corp., Madison, WI) contains a gene encoding chloramphenicol acyltransferase. The level of transient expression of the cat gene in cells that are transfected with pRSV cat was measured with a standard CAT assay.

10 Table 1 compares the results obtained after transfecting SCC 35 cells with pSV40neo and pRSVcat using the minimum volume entrapment (MVE) liposomal transfection method of the present invention, with the results obtained with DEAE-dextran under standard conditions, with calcium phosphate under standard condition, and with a commercially available cationic 15 lipid reagent (Lipofectin, Life Technologies, Gaithersburg, MD) under conditions recommended by the manufacturer.

Table 1

Transfection Efficiency: MVE-Liposomes Compared with Conventional Methods		
Method	Relative Transfection Efficiency Units	
	Stable Transfection ¹	Transient Transfection ²
DEAE-dextran	1	1
Calcium phosphate	1.7	7.5
Lipofectin™ reagent (Life Technologies)	2.3	ND
MVE Liposomes	7	14

1 - Stable transfection efficiency was determined by selecting in G418 containing medium squamous carcinoma SCC 35 cells transfected with pSV40 neo plasmid.

30 2 - Transient transfection efficiency was ascertained following transfection of SCC 35 cells with pRSV cat plasmid and identification by immunofluorescence of cells producing CAT protein.

These results demonstrate that nucleic acids encapsulated in liposomes according to the present invention provide for greatly enhanced transfection efficiencies relative to other available techniques, e.g., DEAE-dextran, calcium phosphate and Lipofectin™ reagent mediated transfection. While not wishing to be bound by any theory of mechanism of action, the present inventors believe that the enhanced transfection efficiencies seen with the method of the present invention are attributable to its high encapsulation efficiency, which provides a liposome population in which a very high percentage of the liposomes contain encapsulated nucleic acids.

EXAMPLE 3: Cellular Uptake of Liposomally Encapsulated Plasmid DNA

Plasmid DNA (18kb) was nick translated with ^{35}S under standard conditions. See Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, Second Edition, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989). This DNA was then encapsulated in liposomes as described in Example 1. The liposomes were constituted from dimyristoyl phosphatidylglycerol, phosphatidylethanolamine and cholesterol in a 5:5:7 ratio, as described in Example 1. This liposomal solution was added to a culture of SCC35 squamous cell carcinoma cells seeded in microchamber glass slides, at a final liposome concentration of 1 μM . The cells were than incubated for 24 h, after which they were washed and then subjected to emulsion autoradiography. This showed a dense array of black dots, corresponding to the presence of radioactively labeled plasmid DNA, in the intracellular compartment and surrounding the cell surface. These results demonstrated that liposomal DNA was effectively taken up by the cells, and penetrated All publications and patent applications mentioned in this specification are indicative of the level of skill of those in the art to which the invention pertains. Although the foregoing refers to particular

preferred embodiments, it will be understood that the present invention is not so limited. It will occur to those of ordinary skill in the art that various modifications may be made to the disclosed embodiments 5 and that such modifications are intended to be within the scope of the present invention, which is defined by the following claims.

What Is Claimed Is:

1. A method for preparing a liposome-encapsulated nucleic acid, comprising the steps of:

(i) incubating a hydrated lipid film for an effective time at reduced temperature, wherein said hydrated lipid film is formed by addition of a concentrated aqueous solution of a high molecular weight nucleic acid to a dried lipid film;

5 10 (ii) adding a minimum effective amount of phosphate buffered saline solution to the hydrated lipid film and vortexing for a time sufficient to generate liposomes and to swell said liposomes; and

(iii) vortexing the resulting swelled liposomes.

15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999

7. The method according to claim 1, wherein the size of said nucleic acid is from about 1 kB to about 25 kB.

8. The method according to claim 7, wherein the size of said nucleic acid is from about 5 kB to about 18 kB.

5 9. The method according to claim 1, wherein the method further comprises the step of (iv) removing unencapsulated nucleic acid from said liposomes by washing said liposomes.

10 10. The method according to claim 9, wherein said washing is achieved by centrifugation.

11. A method for transfecting cells comprising contacting a cell with an effective amount of swelled nucleic acid-containing liposomes, wherein said liposomes are prepared by the steps of:

15 (i) incubating a hydrated lipid film for an effective time at reduced temperature, wherein said hydrated lipid film is formed by addition of a concentrated aqueous solution of a high molecular weight nucleic acid to a dried lipid film;

20 (ii) adding a minimum effective amount of phosphate buffered saline solution to the hydrated lipid film and vortexing for a time sufficient to generate liposomes and to swell said liposomes; and

(iii) vortexing the resulting swelled liposomes.

25 12. The method according to claim 9, wherein said nucleic acid is a plasmid, a phagemid, or a cosmid.

13. A liposome comprising a high molecular weight nucleic acid, produced by the method of claim 1.

30 14. A liposome preparation comprising a nucleic acid having a size of at least 2 kB, wherein at least 25% of said liposomes contain said nucleic acid.

15. A liposome preparation comprising a nucleic acid having a size of at least 5 kB, wherein at least 10% of said liposomes contain said nucleic acid.

35 16. A transfected cell prepared by the method of claim 11.

17. A liposome prepared by the method of claim 1, wherein said high molecular weight DNA encodes an antisense RNA, a ribozyme, or a therapeutic protein.

5 18. A method for preparing a liposome-encapsulated nucleic acid comprising the steps of:

(i) incubating a hydrated lipid film for about 2 hours at room temperature, wherein said hydrated lipid film is formed by addition of a concentrated aqueous solution of a high molecular weight nucleic acid to a 10 dried lipid film in a ratio of less than or equal to about 1.6 μ l of DNA solution per mg of lipid;

15 (ii) adding a phosphate buffered saline solution to the hydrated lipid film in a ratio of less than or equal to about 1.6 μ l per mg of lipid, and vortexing for a time sufficient to generate liposomes and to swell said liposomes; and

(iii) vortexing the resulting swelled liposomes, whereby at least 25% of said nucleic acid is incorporated in said liposomes.

20 19. A liposome according to claim 17, wherein said therapeutic protein is selected from the group consisting of platelet-derived growth factor, epidermal growth factor, interleukins 1-14, granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor, 25 tumor necrosis factor, leukemia inhibitory factor, amphiregulin, angiogenin, betacellulin, calcitonin, ciliary neurotrophic factor, brain-derived neurotrophic factor, neurotrophins 3 and 4, nerve growth factor, colony stimulating factor-1, endothelial cell growth factor, erythropoietin, acidic and basic, fibroblast growth factor, hepatocyte growth factor, heparin binding EGF-like growth factor, insulin, insulin-like growth factors I and II, interferons α , β , and γ , keratinocyte growth factor, macrophage inflammatory protein α and β , 30 midkine, oncostatin M, RANTES, stem cell factor, transforming growth factors α and β , and vascular endothelial growth factor.

20. A liposome according to claim 17, wherein said high molecular weight DNA encodes a tissue-specific promoter.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/08619

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 9/127
US CL : 424/450; 935/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/450; 935/54

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

NONE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PINNADUWAGE et al. Use of quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells. Biochimica et Biophysica Acta. 1989, Vol. 985, pages 33-37, especially page 34.	1-20
Y	US 4,902,512 A (ISHIGAMI ET AL.) 20 February 1990 (20.02.90), column 4, lines 25-47.	1-20
Y	US 4,762,720 A (JIZOMOTO) 09 August 1988 (09.08.88), column 6, lines 13-39.	1-20

Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"		document defining the general state of the art which is not considered to be of particular relevance
"E"	"X"	earlier document published on or after the international filing date
"L"		document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)
"O"	"Y"	document referring to an oral disclosure, use, exhibition or other means
"P"	"&"	document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search 08 JULY 1996	Date of mailing of the international search report 24 JUL 1996
---	---

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

G. S. KISHORE

Telephone No. (703) 308-2351

